Although investors should take these results with a grain of salt, Gilead Sciences remains one step ahead of most other companies that are looking to develop treatments for the novel coronavirus.The phase 2 part of the trial will be conducted in several countries and will test NVX-CoV2373's safety, immunity, and disease reduction in a broader age range of participants.